Heterogeneity of Cancer-Associated Fibroblasts and Precision Targeting Strategies for Cancer Therapy

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Immune checkpoint blockade (ICB) therapy shows promise in cancer treatment but faces limitations due to the immunosuppressive tumor microenvironment (TME).
• Cancer-associated fibroblasts (CAFs) are key stromal cells within the TME, contributing significantly to immune evasion and therapeutic resistance.
• CAFs exhibit heterogeneity and plasticity, influencing their role in tumor progression and response to therapy.

Purpose of the Study:

• To review the multifaceted roles of cancer-associated fibroblasts (CAFs) in mediating tumor immunosuppression and resistance to immune checkpoint blockade (ICB).
• To highlight the heterogeneity and plasticity of CAFs and their impact on therapeutic efficacy.
• To advocate for a shift towards targeting specific CAF states and regulatory pathways for improved cancer treatment strategies.

Main Methods:

• Literature review focusing on the contributions of CAFs to the immunosuppressive TME.
• Analysis of CAF heterogeneity, plasticity, and interactions with immune cells.
• Discussion of emerging therapeutic strategies targeting CAFs and advanced technologies for CAF research.

Main Results:

• CAFs promote tumor immune evasion by remodeling the extracellular matrix, impairing T-cell function, and interacting with immune and myeloid cells.
• CAF heterogeneity and plasticity are critical determinants of therapeutic resistance and efficacy.
• Current CAF-targeted therapies are evolving towards strategies focusing on specific subpopulations and functional reprogramming.

Conclusions:

• Understanding CAF heterogeneity and plasticity is crucial for overcoming ICB resistance.
• Targeting specific CAF states and regulatory pathways, rather than broad clearance, offers a more effective therapeutic approach.
• Integrating advanced technologies like spatial omics and single-cell analysis will enable precise targeting of CAFs and biomarker discovery for personalized cancer therapy.